ALUMIS INC. - COMMON STOCK

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

06 Feb 2025 15:15:00 By Nasdaq GlobeNewswire

Alumis Strengthens Leadership Team with Key Appointments

28 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

19 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

14 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

13 Nov 2024 15:05:48 By Nasdaq GlobeNewswire

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

04 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

27 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Alumis to Participate in Upcoming September Investor Conferences

03 Sep 2024 15:29:30 By Nasdaq GlobeNewswire

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

13 Aug 2024 15:05:27 By Nasdaq GlobeNewswire

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

29 Jul 2024 07:00:00 By Nasdaq GlobeNewswire